New therapeutic antibodies for coronary pneumonia developed by Institute of Microbiology of Chinese Academy of Sciences enter clinical trials

Introduction: This marks the successful entry of the new coronavirus-specific antibody drug with China's independent intellectual property rights into the human clinical evaluation stage
June 5, 2020, the State Drug Administration officially approved the Chinese Academy of Sciences Institute of Microbiology anti-epidemic science and technology team developed a new crown virus whole human-derived monoclonal antibody clinical trial application, Phase I clinical trial will be in healthy human body safety and dose testing, which is the firstthe world has completed a new type of non-human primate test, in the healthy populationthis marks the successful entry of the new coronavirus-specific antibody drug withChina's independent intellectual property rights into the clinical evaluation stage of human bodyfrom mid-January, the Institute of Microbiology of the Chinese Academy of Sciences quickly set up a number of anti-epidemic science and technology team, to meet the difficulties and overcome difficultiesYan Jinghua researcher team in the antibody drug day after day diligent, adhere to the science to the epidemic prevention and control of the answer and methodThe dozens of all-human antibody genes isolated from patients discharged from the hospital with new coronary pneumonia were isolated and compared with trial and error, and 2 ideal special-effect antibodies were screened in late February, with high-efficiency activity of the chinese and new coronavirusThe team evaluated the effectiveness of the antibodies using the rhesus monkey's new coronavirus infection model, and the results showed that:neutralizing antibodies effectively blocked the infection of the new coronavirus, significantly reduced the load of the new coronavirus in the respiratory tract of the rhesus monkey, and protected the lung damage caused by the virus infectionthe outbreak of new crown pneumonia is spreading rapidly around the world, with more than 6.6 million people infectedScientists around the world are actively working to find effective drugs to fight the new coronavirus, but no special-effects drugs for the new coronaal pneumonia have yet been approved for marketNeutralizing antibodies is a class of specific immunoglobulins that target pathogens and block pathogens from invading cells, and are innovative and special drugs developed for new coronavirusesThe development of clinical trials of antibody drugs has brought new hope to curb the spread of the new coronavirusantibody research and development work has been the State Council's joint prevention and control mechanism, the Chinese Academy of Sciences, the Ministry of Science and Technology, the National Health and Health Commission, the State Drug Administration and the Beijing Municipal Science and Technology Commission and other departments of the full support, fully reflects the national system in the major drug research and development of the great advantagesfrom entering the human clinical trial stage, to the final use of antibody drugs, there is still a long way to go, the results of the hard-won, the future still has a long way to goarticle from the Institute of Microbiology of the Chinese Academy of Sciences, the author of the Institute of Microbiology of the Chinese Academy of Sciences